OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) - PROTEOSTASIS THERAPEUTICS IN ownership

PROTEOSTASIS THERAPEUTICS IN's ticker is PTI and the CUSIP is 74373B109. A total of 41 filers reported holding PROTEOSTASIS THERAPEUTICS IN in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) ownership history of PROTEOSTASIS THERAPEUTICS IN
ValueSharesWeighting
Q4 2018$262,000,000
-61.9%
80,903
-31.4%
0.01%
-25.0%
Q4 2017$688,000,000
+450.4%
118,000
+806.6%
0.01%
+500.0%
Q1 2016$125,000,00013,0160.00%
Other shareholders
PROTEOSTASIS THERAPEUTICS IN shareholders Q2 2016
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 3,804,027$17,803,0002.95%
HARBOURVEST PARTNERS LLC 440,627$2,062,0000.89%
NEA Management Company, LLC 3,556,778$16,646,0000.61%
Rock Springs Capital Management LP 450,000$2,106,0000.11%
Bain Capital Public Equity Management, LLC 263,498$1,233,0000.07%
ELEMENT CAPITAL MANAGEMENT LLC 65,973$309,0000.06%
Hillhouse Capital Management 865,923$4,053,0000.06%
SABBY MANAGEMENT, LLC 125,151$586,0000.04%
Marshall Wace North America L.P. 684,124$3,421,0000.02%
FNY Partners Fund LP 20,127$94,0000.02%
View complete list of PROTEOSTASIS THERAPEUTICS IN shareholders